2. Akashi D, Issa FK, Pereira AC, Tannuri AC, Fucciolo DQ, Lobato ML, et al. [Antihypertensive treatment. Prescription and cost of drugs. Survey in a tertiary care hospital]. Arq Bras Cardiol. 1998;71(1):55-7.
3. Akhavan D, Musgrove P, Abrantes A, d'A Gusmão R. Cost-effective malaria control in Brazil. Cost-effectiveness of a Malaria Control Program in the Amazon Basin of Brazil, 1988-1996. Soc Sci Med. 1999;49(10):1385-99.
4. Almeida AM, da Silva AL, Cherchiglia ML, Andrade EIG, de Oliveira GLA, de Assis Acurcio F. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. Value Health. 2011;14(5 Suppl 1):S24--S8.
5. Araújo DV, Kirk K, Lopes AJ, Rocha JLd. Pharmacoeconomic analysis of salmeterol/fluticasone propionate combination versus systemic corticosteroids and oral B-adrenergic agents in Brazilian Unified Health System for the management of asthma. Pulmäo RJ. 2006;15(1):20-3.
6. Araujo DV, de Souza CPR, Bahia LR, Rey HCV, Junior BDS, Tura BR, et al. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system]. Value Health. 2011;14(5 Suppl 1):S29--S32.
7. Araujo DV, Tavares LR, Veríssimo R, Ferraz MB, Mesquita ET. [Cost of heart failure in the Unified Health System]. Arq Bras Cardiol. 2005;84(5):422-7.
8. Araújo DV, Teich V, Passos RBF, Martins SCO. Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke. Arq Bras Cardiol. 2010;95(1):12-20.
9. Argenta C, Ferreira MAP, Sander GB, Moreira LB. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis. Value Health. 2011;14(5 Suppl 1):S89--S92.
10. Aspler A, Long R, Trajman A, Dion M-J, Khan K, Schwartzman K, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax. 2010;65(7):582-7.
11. Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leão MPS, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14(5 Suppl 1):S137--S40.
12. Barros AJD, Bertoldi AD. Out-of-pocket health expenditure in a population covered by the Family Health Program in Brazil. Int J Epidemiol. 2008;37(4):758-65.
13. Barth-Jones DC, Cheng H, Kang LY, Kenya PR, Odera D, Mosqueira NR, et al. Cost effectiveness and delivery study for future HIV vaccines. AIDS. 2005;19(13):w1--w6.
14. Bertoldi AD, Barros AJD, Camargo AL, Hallal PC, Vandoros S, Wagner A, et al. Household expenditures for medicines and the role of free medicines in the Brazilian public health system. Am J Public Health. 2011;101(5):916-21.
15. Bertoldi EG, Rohde LE, Zimerman LI, Pimentel M, Polanczyk CA. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. Int J Cardiol. 2011.
16. Boing AC, Bertoldi AD, Peres KG. Socioeconomic inequalities in expenditures and income committed to the purchase of medicines in Southern Brazil. Rev Saude Publica. 2011;45(5):897-905.
17. Brandão CMR, Guerra AA, Cherchiglia ML, Andrade EIG, Almeida AM, da Silva GD, et al. [Expenses of the Brazilian Ministry of Health for high-cost drugs: a demographic and clinical analysis]. Value Health. 2011;14(5 Suppl 1):S71--S7.
18. Brentani A, de Castro G, Federico MH. Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil. Head Neck. 2011;33(8):1199-205.
19. Burckel E, Ashraf T, de Sousa Filho JP, Neto EF, Guarino H, Yauti C, et al. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics. 1999;16(5 Pt 2):563-76.
20. Carias CM, Vieira FS, Giordano CV, Zucchi P. Exceptional circumstance drug dispensing: history and expenditures of the Brazilian Ministry of Health. Rev Saude Publica. 2011;45(2):233-40.
21. Castelo A, Pessôa MG, Barreto TCBB, Alves MRD, Araújo DV. [Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005]. Rev Assoc Med Bras. 2007;53(6):486-91.
22. Centenari C, Gurgel RQ, Bohland AK, Oliveira DMP, Faragher B, Cuevas LE. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine. 2010;28(25):4162-8.
23. Cestari T, Adjadj L, Hux M, Shimizu MR, Rives VP. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007;6(2):153-60.
24. Chermont GC, Kowalski SC, Ciconelli RM, Ferraz MB. Resource utilization and the cost of rheumatoid arthritis in Brazil. Clin Exp Rheumatol. 2008;26(1):24-31.
25. Coelho JC, Wiederkehr JC, Lacerda MA, Campos AC, Neto CZ, Matias JE, et al. [Cost of liver transplantation at the Clinical Hospital of the University of Parana, Brazil]. Rev Assoc Med Bras. 1997;43(1):53-7.
26. Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr. 2008;26(4):388-96.
27. Costa AMN, italien GL, Nita ME, Araujo ESA. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis. 2008;12(5):368-73.
28. Costa JG, Santos AC, Rodrigues LC, Barreto ML, Roberts JA. [Tuberculosis in Salvador, Brazil: costs to health system and families]. Rev Saude Publica. 2005;39(1):122-8.
29. Costa VC, Ferraz MB, Petrilli AS, Pereira CA, Rogerio JW. Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas. Support Care Cancer. 2003;11(6):356-61.
30. da Costa JSD, Fuchs SC, Olinto MTA, Gigante DP, Menezes AMB, Macedo S, et al. Cost-effectiveness of hypertension treatment: a population-based study. Sao Paulo Med J. 2002;120(4):100-4.
31. da Saúde. Secretaria de Ciência TeIEgDdCneT. Diretrizes metodológicas: estudos de avaliação econômica de tecnologias de saúde. p. -.
32. da Silva GD, de Assis Acúrcio F, Cherchiglia ML, Júnior AAG, Andrade EIG. [Dispensing of exceptional drugs for chronic renal failure: expenditures and patients' profile in Minas Gerais State, Brazil]. Cad Saude Publica. 2011;27(2):357-68.
33. Dal-Paz K, Oliveira PRD, de Paula AP, da S Emerick MC, Pécora JR, Lima ALLM. Economic impact of treatment for surgical site infections in cases of total knee arthroplasty in a tertiary public hospital in Brazil. Braz J Infect Dis. 2010;14(4):356-9.
34. Daltio CS, Mari JJ, Ferraz MB. Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. Rev Saude Publica. 2011;45(1):14-23.
35. de Assis Acurcio F, Puig-Junoy J, de Fátima Bonolo P, das Graças Braga Ceccato M, Guimarães MDC. [Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil]. Rev Esp Salud Publica.80(1):41-54.
36. de Soarez PC, Sartori AMC, de Andrade Lagoa Nóbrega L, Itria A, Novaes HMD. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil. Value Health. 2011;14(8):1019-27.
37. de Soárez PC, Valentim J, Sartori AMC, Novaes HMD. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica. 2008;23(4):221-30.
38. de Sousa Marques HH, Couttolenc BF, do Rosário Dias de Oliveira Latorre M, de Aquino MZ, Aveiro MIG, Pluciennik AMA. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS. Cad Saude Publica. 2007;23 Suppl 3:S402--S13.
39. de Souza e Silva NA, Aguiar GR, da R Nogueira A, Duarte MM, Alves RH. [Clinical importance of direct hospital costs in patients with arterial hypertension in a university hospital, Rio de Janeiro, Brazil]. Rev Saude Publica. 1986;20(4):293-302.
40. de Souza MV, Krug BC, Picon PD, Schwartz IVD. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders]. Cien Saude Colet. 2010;15 Suppl 3:3443-54.
41. de Tolêdo Nóbrega O, Marques AR, de Araújo ACG, de Oliveira Karnikowski MG, de Oliveira Silva Naves J, Silver LD. Retail prices of essential drugs in Brazil: an international comparison. Rev Panam Salud Publica. 2007;22(2):118-23.
42. Desgualdo CM, Riera R, Zucchi P. Cost estimate of hospital stays for premature newborns in a public tertiary hospital in Brazil. Clinics (Sao Paulo). 2011;66(10):1773-7.
43. Dib MW, Riera R, Ferraz MB. Estimated annual cost of arterial hypertension treatment in Brazil. Rev Panam Salud Publica. 2010;27(2):125-31.
44. Drummond M, Ferraz MB, Mason J. Assessing the cost effectiveness of NSAID: an international perspective. J Rheumatol. 1995;22(7):1408-11.
45. Ferraz ML, de Oliveira PM, Figueiredo VM, Kemp VL, Filho AC, Silva AE. [The optimization of the use of economic resources for vaccination against hepatitis B in professionals in the health area]. Rev Soc Bras Med Trop. 1995;28(4):393-403.
46. Fonseca MCM, de Araújo GTB, Araújo DV. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz J Infect Dis. 2009;13(3):191-9.
47. Fonseca MCM, de Araújo GTB, Etto H, Schiola A, Santoni N, Machado M. Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil. Clin Ther. 2011;33(11):1769--80.e2.
48. Fonseca M, Araújo GTB, Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras. 2009;55(4):410-5.
49. Fonseca SN, Kunzle SRM, Silva SAB, Schmidt JG, Mele RR. Cost reduction with successful implementation of an antibiotic prophylaxis program in a private hospital in Ribeirão Preto, Brazil. Infect Control Hosp Epidemiol. 1999;20(1):77-9.
50. Jardim JR. Pharmacological economics and asthma treatment. J Bras Pneumol. 2007;33(1):iv--vi.
51. Junior AAG, de Assis Acúrcio F, Andrade EIG, Cherchiglia ML, Cesar CC, de Queiroz OV, et al. [Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison]. Cad Saude Publica. 2010;26(1):163-74.
52. Kanamura AH, Viana ALDA. [High expenditure on a private healthcare plan: for whom and in what]. Rev Saude Publica. 2007;41(5):814-20.
53. Krauss-Silva L. [Technology assessment in health care: methodological and operational questions]. Cad Saude Publica. 2004;20 Suppl 2:S199--S207.
54. Lima MG, Ribeiro AQ, Acurcio FdA, Rozenfeld S, Klein CH, de Assis Acurcio F. [Out-of-pocket drug expenditures by retirees and pensioners 60 years and older in Belo Horizonte, Minas Gerais, Brazil]. Cad Saude Publica. 2007;23(6):1423-30.
55. Lindner LM, Marasciulo AC, Farias MR, Grohs GEM. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009;43 Suppl 1:62-9.
56. Massad E, Coutinho FAB, Chaib E, Burattini MN. Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy. Epidemiol Infect. 2009;137(2):241-9.
57. Massad E, Behrens BC, Coutinho FAB, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Malar J. 2011;10:130-.
58. Mesquita SRAM, Anselmi ML, dos Santos CB, Hayashida M. [Interdisciplinary home hospitalization program of Marília-SP: material resource costs]. Rev Lat Am Enfermagem. 2005;13(4):555-61.
59. Miravitlles M, Jardim JR, Zitto T, Rodrigues JE, López H. [Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America]. Arch Bronconeumol. 2003;39(12):549-53.
60. Moreira GC, Cipullo JP, Martin JFV, Ciorlia LAS, Godoy MRP, Cesarino CB, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. J Hypertens. 2009;27(9):1900-7.
61. Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Williston Park). 1997;11(9 Suppl 10):128-35.
62. Neto JT, de Araujo GTB, Gagliardi A, Pinho A, Durand L, Fonseca M. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. Hum Vaccin. 2011;7(10):1037-47.
63. Nita ME, Secoli SR, Nobre M, Ono-Nita SK. [Health technology assessment: research methodology]. Arq Gastroenterol. 2009;46(4):252-5.
64. Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med. 2007;4(11):e305-e.
65. Ozelo MC, Villaça PR, Almeida JOSCD, Bueno TMF, Miranda PAPD, Hart WM, et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia. 2007;13(5):462-9.
66. Pereira SM, Barreto ML, Pilger D, Cruz AA, Sant'anna C, Hijjar MA, et al. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial. Lancet Infect Dis. 2012;12(4):300-6.
67. Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol. 2007;88(4):464-74.
68. Portela MP, Neri EDR, Fonteles MMF, Garcia JHP, Fernandes MEP. [The cost of liver transplantation at a university hospital of Brazil]. Rev Assoc Med Bras. 2010;56(3):322-6.
69. Ramos MLcT, Taliberti H, Sigulem F, Caro J, Caro I, Zucchi P. The process of including new pharmaceutical drugs in the formularies of health care institutions. Rev adm saúde. 2008;10(38):21-8.
70. Reinharz D, Saldaña VR, Follador W, Asche C. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations. Int J Technol Assess Health Care. 2001;17(4):571-8.
71. Ribeiro RA, Mello RGB, Melchior R, Dill JC, Hohmann CB, Lucchese AM, et al. [Annual cost of ischemic heart disease in Brazil. Public and private perspective]. Arq Bras Cardiol. 2005;85(1):3-8.
72. Santos LA, Oliveira MA, Faresin SM, Santoro IL, Fernandes ALG. Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients. Braz J Med Biol Res. 2007;40(7):943-8.
73. Sartori AMC, de Soárez PC, Novaes HMD. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Community Health. 2012;66(3):210-7.
74. Sasse AD, Sasse EC. [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer]. Rev Assoc Med Bras. 2009;55(5):535-40.
75. Secoli SR, Nita ME, Ono-Nita SK, Nobre M. [Health technology assessment: II. Cost effectiveness analysis]. Arq Gastroenterol. 2010;47(4):329-33.
76. Secoli SR, Padilha KG, Litvoc J. Cost-effectiveness analysis of the analgesic therapy of postoperative pain. Rev Lat Am Enfermagem. 2008;16(1):42-6.
77. Silva LK. [Technology assessment in health care: bone densitometry and alternative therapies in post-menopausal osteoporosis]. Cad Saude Publica. 2003;19(4):987-1003.
78. Stefani SD, Saggia MG, dos Santos EAV. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. J Med Econ. 2008;11(3):383-96.
79. Steffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, Monteiro P, et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One. 2010;5(11):e14014-e.
80. Stillitano IG, de Lima MG, Ribeiro MP, Cabral J, Brandt CT. [Economic impact of eyedrop cost in glaucoma treatment]. Arq Bras Oftalmol. 2005;68(1):79-84.
81. Takemoto MLS, Fernandes RA, Almeida GR, Monteiro RDC, Colombini-Neto M, Bertola-Neto A. Health care resource use and costs in opioid-treated patients with and without constipation in Brazil. Value Health. 2011;14(5 Suppl 1):S78--S81.
82. Ugá MAD. Economic analysis of the vaccination strategies adopted in Brazil in 1982. Bull Pan Am Health Organ. 1988;22(3):250-68.
83. Valentim J, Sartori AMC, de Soárez PC, Amaku M, Azevedo RS, Novaes HMD. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine. 2008;26(49):6281-91.
84. Valentim J, Passos V, Mataveli F, Calabró A. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol. 2008;52(9):1452-60.
85. Vanni T, Fonseca BAL, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil. HIV Clin Trials. 2006;7(4):194-202.
86. Vanni T, Luz PM, Ribeiro RA, Novaes HMD, Polanczyk CA. [Economic evaluation in health: applications in infectious diseases]. Cad Saude Publica. 2009;25(12):2543-52.
87. Vespa G, Constenla DO, Pepe C, Safadi MA, Berezin E, Moraes JCD, et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. American Journal of Public Health. 2009;2015(7):518-28.
88. Vieira FS. Ministry of Health's spending on drugs: program trends from 2002 to 2007. Rev Saude Publica. 2009;43(4):674-81.
89. Vieira FS, Zucchi P. [Price differences between generic and innovator medicines in Brazil]. Rev Saude Publica. 2006;40(3):444-9.
90. Vieira FS, Zucchi P. Resource allocation for pharmaceutical procurement in the Brazilian Unified Health System. Rev Saude Publica. 2011;45(5):906-13.
91. Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.
92. Zahdi MR, Maluf I, Maluf EMCP. Hepatitis A: the costs and benefits of the disease prevention by vaccine, Paraná, Brazil. Braz J Infect Dis. 2009;13(4):257-61.
Nenhum comentário:
Postar um comentário